News | August 03, 2025
Beta-HPV can directly cause skin cancer in immunocompromised people
cSCC is one of the most common cancers in the U.S. and globally
cSCC is one of the most common cancers in the U.S. and globally
The SURPASS-CVOT study met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity
The INSPIRE-1 and INSPIRE-2 trials are Phase 3 studies assessing the efficacy and safety of tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis (PsA)
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
Additional data will be presented on a once-weekly oral combination of islatravir and ulonivirine (ISL/ULO) for HIV-1 treatment
These medicines are essential in preventing RhD immunisation during pregnancy
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells
atai and Beckley Psytech plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to finalize the Phase 3 trial design.
Subscribe To Our Newsletter & Stay Updated
